For decades, onchocerciasis (or river blindness) was one of the most common infectious causes of blindness in the world. Primarily an infection of Africa, with limited distribution in the new world, disease due to the nematode Onchocerca volvulus is rapidly diminishing as a result of large public health campaigns targeting at risk populations in Africa and the Americas. Existing and newly-developed treatment strategies offer the chance to eliminate onchocercal ocular morbidity in some parts of the world. This article reviews these treatment strategies, current clinical and epidemiologic aspects of onchocerciasis, and the next steps toward elimination.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC3125028 | PMC |
| http://dx.doi.org/10.4103/0974-777X.81692 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The Spectrum of Ocular Diseases in the Onchocerciasis-Endemic Focus of Raga in South Sudan.
Res Rep Trop Med
December 2024
Global Health Institute, University of Antwerp, Antwerp, Belgium.
Introduction: Raga County is an onchocerciasis-endemic area in the Western Bahr El Ghazal state of South Sudan, known to have a high prevalence of blindness. The objective of this study was to determine the causes of eye disease and blindness in Raga County as well as to assess the relationship of eye diseases with other prevalent conditions like onchocerciasis and epilepsy.
Methods: We reviewed unpublished pre-community directed treatment with ivermectin (CDTI) data about eye disease and onchocerciasis in Western Bahr El Ghazal including Raga.
Ivermectin as a promising therapeutic option for onchocerciasis-associated epilepsy.
Epilepsia Open
November 2024
Experimental Medicine Research Center, Tehran University of Medical Sciences, Tehran, Iran.
Onchocerciasis, commonly known as river blindness, is a neglected tropical disease caused by the parasite Onchocerca volvulus. It can lead to blindness and visual impairment. Studies have also demonstrated a link between onchocerciasis and epilepsy, with there being a correlation between onchocerciasis endemicity and epilepsy prevalence.
View Article and Find Full Text PDFCrystal structure of N-terminally hexahistidine-tagged Onchocerca volvulus macrophage migration inhibitory factor-1.
Acta Crystallogr F Struct Biol Commun
December 2024
Dartmouth Cancer Center, One Medical Center Drive, Lebanon, NH 03756, USA.
Article Synopsis
- Onchocerca volvulus is responsible for serious health issues, including blindness and neurological diseases, and current treatments like ivermectin can't be safely used in pregnant women or those co-infected with Loa loa.
- Researchers at the Seattle Structural Genomics Center for Infectious Disease have successfully produced and crystallized a potential drug target called OvMIF-1, which has a unique jellyfish-like structure.
- The study suggests that deleting its N-terminal tag could reveal a larger cavity for drug targeting, indicating the need for further analysis to confirm the true biological structure of OvMIF-1.
Spatial proteomics of with pleomorphic neoplasms shows local and systemic dysregulation of protein expression.
bioRxiv
October 2024
Infectious Diseases Division, Department of Medicine, Washington University School of Medicine, St. Louis, MO 63110, USA.
is the agent of onchocerciasis (river blindness) and targeted by WHO for elimination though mass drug administration with ivermectin. A small percentage of adult worms develop pleomorphic neoplasms (PN) that are positively associated with the frequency of ivermectin treatment. Worms with PN have a lower life expectancy and a better understanding about the proteins expressed in PN, and how PN affect protein expression in different tissues could help to elucidate the mechanisms of macrofilaricidal activity of ivermectin.
View Article and Find Full Text PDFPredictive immunoinformatics reveal promising safety and anti-onchocerciasis protective immune response profiles to vaccine candidates (Ov-RAL-2 and Ov-103) in anticipation of phase I clinical trials.
PLoS One
October 2024
Department of Biochemistry and Molecular Biology, Faculty of Science, University of Buea, Buea, Cameroon.
Onchocerciasis (river blindness) is a debilitating tropical disease that causes significant eye and skin damage, afflicting millions worldwide. As global efforts shift from disease management to elimination, vaccines have become crucial supplementary tools. The Onchocerciasis Vaccine for Africa (TOVA) Initiative was established in 2015, to advance at least one vaccine candidate initially targeting onchocerciasis in infants and children below 5 years of age, through Phase I human trials by 2025.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!